Pentraxin3 Case Study
Objectives: Pentraxin3 is a novel biomarker produced by vascular endothelial cells and macrophages. In recent studies involving adults, Pentraxin 3 has been introduced as a reliable biomarker in the evaluation of cardiovascular disease and pulmonary hypertension. This study was conducted with an aim to measure the level of Pentraxin 3 in neonates with pulmonary hypertension and comparing with normal healthy controls.
Design and Methods: In a case-control study, plasma Pentraxin 3 levels were evaluated in 3 groups of neonates including: neonates with pulmonary arterial hypertension (PAH), neonates with congenital heart disease without pulmonary arterial hypertension (CHD without PAH) and normal healthy neonates, during October 2013 to March …show more content…
Pentraxin3 (PTX3) is a biomarker like C-reactive protein (CRP) which belongs to Pentraxin superfamily. CRP is a short Pentraxin originated from liver, whereas PTX3 is a long Pentraxin that is highly expressed in the heart and synthesized by vascular endothelial cells and macrophages [5,6,7,8]. PTX3 has a well-established role in the innate immune response to infection [9,10]. Serum level of PTX3 has a correlation with severity of infectious disease and can be used as an independent prognostic biomarker in bacteriemia and fatal diseases [11,12]. Many studies showed that PTX3 is a widely used biomarker in clinical situations [12,13]. Recently, the role of PTX3 in cardiovascular diseases has been demonstrated in several studies [13,14]. It has been shown that the level of PTX3 elevated in the acute myocardial infarction and congestive heart failure [7,8]. The role of PTX3 as a specific biomarker for the diagnosis of PAH has also been recently demonstrated [5].
Most PTX3 –related cardiovascular disease studies are limited to adult patients; only a few studies have been carried out on clinical utility of PTX3 as a biomarker in neonatal morbidities. To the best of our knowledge, PTX3 has not been fully evaluated in newborn infants with PAH. Therefore we examined the role of plasma PTX3 in neonates with a diagnosis of pulmonary arterial
Design and Methods: In a case-control study, plasma Pentraxin 3 levels were evaluated in 3 groups of neonates including: neonates with pulmonary arterial hypertension (PAH), neonates with congenital heart disease without pulmonary arterial hypertension (CHD without PAH) and normal healthy neonates, during October 2013 to March …show more content…
Pentraxin3 (PTX3) is a biomarker like C-reactive protein (CRP) which belongs to Pentraxin superfamily. CRP is a short Pentraxin originated from liver, whereas PTX3 is a long Pentraxin that is highly expressed in the heart and synthesized by vascular endothelial cells and macrophages [5,6,7,8]. PTX3 has a well-established role in the innate immune response to infection [9,10]. Serum level of PTX3 has a correlation with severity of infectious disease and can be used as an independent prognostic biomarker in bacteriemia and fatal diseases [11,12]. Many studies showed that PTX3 is a widely used biomarker in clinical situations [12,13]. Recently, the role of PTX3 in cardiovascular diseases has been demonstrated in several studies [13,14]. It has been shown that the level of PTX3 elevated in the acute myocardial infarction and congestive heart failure [7,8]. The role of PTX3 as a specific biomarker for the diagnosis of PAH has also been recently demonstrated [5].
Most PTX3 –related cardiovascular disease studies are limited to adult patients; only a few studies have been carried out on clinical utility of PTX3 as a biomarker in neonatal morbidities. To the best of our knowledge, PTX3 has not been fully evaluated in newborn infants with PAH. Therefore we examined the role of plasma PTX3 in neonates with a diagnosis of pulmonary arterial